In congruence with the central role of VEGF, the humanized, VEGF-neutralizing monoclonal antibody bevacizumab is approved for treatment of several cancers, including late-stage colon cancer and breast cancer, in conjunction with chemotherapy [1, 7]. The gene discussed is VEGFA; the disease is cancer.